Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 7 sources
Summary
Guideline-based first-line options for symptomatic or progressive autoimmune pulmonary alveolar proteinosis are whole lung lavage and inhaled GM-CSF. The studied molgramostim regimen is 300 µg daily using a dedicated investigational eFlow nebulizer system. Expanded access requests must come from a licensed pulmonologist and do not guarantee treatment access. Savara has selected an exclusive U.S. specialty pharmacy, with commercial distribution and patient assistance contingent on approval.